Cargando…

Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report

BACKGROUND: Programmed cell death protein-1 (PD-1) or its ligand PD-L1 monoclonal antibodies, opening a new era of tumor immunotherapy, and they have significantly improved the overall survival of many patients with advanced solid tumors. However, in addition to its effectiveness, we should also pay...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Rui, Ju, Yinghui, Long, Tengfei, Su, Zhuping, Zhu, Gaochao, Liu, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459630/ https://www.ncbi.nlm.nih.gov/pubmed/36093549 http://dx.doi.org/10.21037/tcr-22-426

Ejemplares similares

Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation
por: Song, Geng, et al.
Publicado: (2022)

Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports
por: Hui-Mei, Pang, et al.
Publicado: (2023)

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation
por: Yin, Liang, et al.
Publicado: (2022)

Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
por: Ding, Qi, et al.
Publicado: (2023)

A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia
por: Fu, Shujuan, et al.
Publicado: (2023)

Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation
por: Liu, Yi, et al.
Publicado: (2023)

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
por: Wang, Feng, et al.
Publicado: (2020)

Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report
por: Liu, Jin, et al.
Publicado: (2023)

Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event
por: Wu, Ping-Shang, et al.
Publicado: (2022)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
por: Qi, Wenbo, et al.
Publicado: (2023)

Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study
por: Wu, Jianhui, et al.
Publicado: (2023)

Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
por: Ma, Rong, et al.
Publicado: (2022)

Acute Paronychia and Reactive Capillary Proliferation in a Patient on Erlotinib
por: Kaur, Ishmeet, et al.
Publicado: (2020)

Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers
por: Wang, Yinhua, et al.
Publicado: (2021)

Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression
por: Chen, Yi-Hui, et al.
Publicado: (2011)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
por: Yang, Qian, et al.
Publicado: (2020)

Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting
por: Qutub, Amina A, et al.
Publicado: (2009)

Immune-Related Colitis Induced by Camrelizumab: A Case Report
por: Cheng, Sheng, et al.
Publicado: (2023)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Case report: Camrelizumab associated with central retinal vein occlusion
por: Zhan, Yixiang, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
por: Lin, Jieheng, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

THE RELATIVE PRESSURES WITHIN CUTANEOUS LYMPHATIC CAPILLARIES AND THE TISSUES
por: McMaster, Philip D.
Publicado: (1947)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
por: Liu, Shaochuan, et al.
Publicado: (2020)

An Integrative Metabolomic and Network Pharmacology Study Revealing the Regulating Properties of Xihuang Pill That Improves Anlotinib Effects in Lung Cancer
por: Li, Chunyu, et al.
Publicado: (2021)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer
por: Yang, Liguo, et al.
Publicado: (2020)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

PRESENCE OF ENDOTHELIAL FENESTRATIONS IN THYMIC CAPILLARIES OF MICE
por: Kramarsky, Bernhard, et al.
Publicado: (1967)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Phase I study of camrelizumab in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
por: Xie, Chengying, et al.
Publicado: (2018)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7vocec2v8htpi06v7hoeg96h2a